Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

lease includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety and progression free survival information for pixantrone which is still being assembled, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, determination the FDA that the PIX301 trial is insufficient to support an NDA filing, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.272.4345

Lindsey Jesch Logan

T : 206.272.4347

F : 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (NYSE: RMD ) today announced results for its ... 2014.  Revenue for the quarter was $415.2 million, flat compared ... decrease on a constant currency basis). Net income was $87.7 ... ended June 30, 2013. Diluted earnings per share for the ... the quarter ended June 30, 2013.  The ...
(Date:7/31/2014)... Therapeutics (Nasdaq: NKTR ) today reported its financial ... Cash and investments in marketable securities at June ... at March 31, 2014."The second half of 2014 will be ... significant milestones for a number of our late-stage clinical programs," ... Nektar. "The first of these is the potential US and ...
(Date:7/31/2014)... Mass. , July 31, 2014 /PRNewswire/ ... funding changes brought about by the Affordable ... reimbursement and prescribing of pharmaceutical therapies. The ... cover beneficiaries through new regulations and expanded ... occurring in the health exchanges—state-based marketplaces set ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... 5, 2010 Sequenom, Inc. (Nasdaq: SQNM ... overview of the company at the following conferences in ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) Lazard Capital ... St. Regis, New York, NY Presentation date: Tuesday ...
... 2010 EnVivo Pharmaceuticals today announced it has discovered ... a novel mechanism not previously seen in the scientific ... to enhance cognition. By acting as a ... possible for smaller amounts of naturally occurring ACh, typically ...
Cached Medicine Technology:Sequenom to Present at Two Financial Conferences in November 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3
(Date:8/1/2014)... According to Forrester Research, more than 90 percent of ... of information, and thanks to the launching of DCInsurers Agent ... resources on insurance specifically for the state of Colorado can ... step in the growth of our business,” Doug King, owner/agent ... Insurance Resources office. “We recognize that the web is how ...
(Date:8/1/2014)... KY (PRWEB) August 01, 2014 Frontier ... Health Resources and Services Administration’s Advanced Education Nursing ... and will provide direct support to 280 students over ... the AENT Program is to increase the number of ... providers and/or nursing faculty to address the nurse faculty ...
(Date:8/1/2014)... and doctors at the Institute of Bioengineering and ... Cancer Centre Singapore (NCCS) have co-developed the first ... survival outcomes in kidney cancer patients. This breakthrough ... the world,s top urology journal. , According ... "By combining our expertise in molecular diagnostics and ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... Utah (PRWEB) August 01, 2014 This ... MonaVie, who completes its 500th week of paying commissions ... the company was founded in January 2005 total $1,405,954,677.06. ... throughout the world. The company pays commissions in 18 ... ILS, JPY, MYR, MXN, NZD, PLN, USD, SGD, KRW, ...
Breaking Medicine News(10 mins):Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
... between Elsevier and Diabetes India. The partnership would be ... Diabetes Research & Metabolic Syndrome in June 2006. // ... relationship between diabetes and metabolic syndrome with special reference ... centered approach in treatment of the disorder. ,Diabetes India ...
... breakthrough, scientists have successfully converted human embryonic stem ... future, replacement cartilage could be grown for transplantation ... problems, including sports injuries, new cartilage for people ... reconstructive surgery. , ,The research, to be ...
... scientists have developed a natural or rather biological pacemaker ... heart muscle cells. The newly developed pacemaker can fire ... the heart in a more physiological way., ,Two ... rise to the heart’s normal rhythm by stimulating other ...
... drugs is on the rise in England, accounting for more ... department each year. , ,The findings are based on ... a hospital in South West England. The doctor in charge ... for treatment with special reference to illegal drug abuse., ...
... previous claims new evidence shows the high fat, low carb ... Atkins (or simply the Atkins' diet) could damage the heart., ... and low // carbohydrates directly affected the heart's ability to ... and colleagues from the Cardiac Metabolism Research Group of Oxford ...
... know that heart disease is ranked as the first ... a new, simple test called dobutamine stress echocardiography that ... , ,The study has been conducted among a ... The study participants underwent a certain type of stress ...
Cached Medicine News:Health News:Partnership Between Diabetes India And Elsevier Announced 2Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Novel Biological Pacemaker Under Construction for Weak Hearts 2Health News:Heart damage a consequence of Atkins’ Die 2Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
... iQ200 Automated Urine Microscopy Analyzer (iQ200) ... (APR) software to classify urine particles ... results. The iQ200 eliminates most technologist ... particle images by automating specimen preparation, ...
... The iQ®200 Sprint Automated Urinalysis System ... fully automated system that performs complete urinalyses ... away. Designed for high volume laboratories or ... The iQ200 Sprint has a processing speed ...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
Medicine Products: